The Efficacy of Additive Tolterodine Extended Release for 1-Year in Older Men with Storage Symptoms and Clinical Benign Proastatic Hyperplasia
Resource
NEUROUROLOGY AND URODYNAMICS v.30 n.4 pp.568-571
Journal
Neurourology and Urodynamics
Pages
568-571
Date Issued
2011
Date
2011
Author(s)
CHUNG, SHIU-DONG
CHANG, HSIAO-CHUN
CHIU, BIN
LIAO, CHUN-HOU
KUO, HANN-CHORNG
Abstract
Aim: To determine the efficacy of toterodine extended release ER treatment for 1 year in older men with benign prostatic hyperplasia BPH and storage symptoms treated with alpha-blockers and/or 5-alpha-reductase inhibitors 5ARI. Methods: Men aged over 70 years with BPH/bladder outlet obstruction BOO and clinical storage symptoms were randomly treated with or without tolterodine ER in combination with alpha-blockers and/or 5ARI for 12 months. Among them, 50 patients group 1 received additive tolterodine extended release ER 4mg q.d., another 87 patients group 2 did not. All patients had a baseline and 12th month post-treatment evaluation, which comprised of uroflowmetry, post-void residual PVR volume, International Prostate Symptom Score IPSS, and quality of life index QoL-I , transrectal ultrasound of the prostate and serum prostate specific antigen. Results: One hundred thirty-seven of 153 enrolled patients with a mean age of 74.9 years completed the study. Treatment benefit demonstrated in both groups included deceased total, voiding and storage IPSS scores, increased peak urinary flow rate and deceased QoL-I. Inter- group difference was only observed on the storage domain of IPSS score P = 0.012. The mean PVR after treatment did not significantly differ between two groups. Two patients of group 1 and three of group 2 developed acute urinary retention. Among group 1, six patients discontinued tolterodine ER for intolerable dry mouth; among group 2, three patients reported dizziness. Conclusions: This longer comparative study indicated that additive treatment with tolterodine ER in older men with BPH/BOO and significant storage symptoms is a beneficial and safe therapeutic option .
Subjects
antimuscarinics
overactive bladder symptoms
prostate